Kun for helsepersonell

Søk

Menu

Close

Logg innLogg ut
LegemiddelTerapiområdeUtforsk merUtforsk merMateriellVideo/podkastNyhetsbrevKontakt oss

Menu

Close

Om ZaviceftaVirkningsmekanismePatogen dekningTidlig hensiktsmessig behandlingIDSA anbefalingØkonomiske holdepunkterSpørsmål og svar om ZAVICEFTAPasientprofilerHAP/VAP pasientcUTI pasientcIAI pasientPediatriske pasienterSpørsmål og svar - FAQsEffekt Real-world evidenceEffektdataSpørsmål og svar om effektSikkerhetSikkerhet hos voksneSikkerhet hos barn/ungdomSpørsmål og svar om sikkerhetDoseringDosering hos voksneDosering hos barn/ungdomSpørsmål og svar om dosering
Patogen dekningZAVICEFTA (ceftazidime–avibactam) has in vitro activity against CRE, including KPC- and OXA-48-producing strains,
MDR P. aeruginosa, and ESBL- and AmpC-producing bacteria1–5

Including a spectrum of activity against Gram-negative pathogens versus other BL/BLI4–16

Scroll left to view table
Download our spectrum of activity one-pager for more information on
ZAVICEFTA’s pathogen coverage in comparison to competitor treatments.
Loading
ZAVICEFTA’s broad-spectrum Gram-negative pathogen coverage can be used across a range of indications1,4*
Scroll left to view table
HAP/VAP

Discover more about HAP/VAP in a clinical setting.

Loading
Infectious Thinking

Listen to our ‘Infectious Thinking’ podcast on Spotify, as top medical experts discuss the challenges of MDR infections in high-risk patients.

Loading
With superior and comparable susceptibility against Gram-negative pathogens vs. competitors17†‡

ESBL/CRE

Enterobacterales/
P. aeruginosa

MDR P. aeruginosa/
XDR P. aeruginosa

Tab Number 4

Tab Number 5

Adapted from Sader HS, et al. 2020 and supplementary information17

Adapted from Sader HS, et al. 2020 and supplementary information17

Adapted from Sader HS, et al. 2020 and supplementary information17

ZAVICEFTA is effective against infections with Enterobacterales and P. aeruginosa with EUCAST minimum inhibitory concentrations as follows:
Scroll left to view table

ZAVICEFTA is active against a broad range of Gram-negative resistance mechanisms, including class A (e.g. ESBL and KPC), class C (e.g. AmpC) and some class D (including OXA-48) β-lactamases.4

Footnotes:

*In vitro data indicate that the following species are not susceptible to ZAVICEFTA: Staphylococcus aureus (methicillin-susceptible and methicillin-resistant strains), anaerobes, Enterococcus spp., Stenotrophomonas maltophilia and Acinetobacter spp.
Isolates from patients hospitalised with pneumonia in US medical centres in 2017–2018 as per EUCAST criteria.17
ZAVICEFTA’s (ceftazidime–avibactam) range of in vitro activity against β-lactamases does not necessarily predict clinical success.9
§The breakpoint is the MIC that is the cut-off between susceptible and resistant isolates. If the MIC is less than or equal to the susceptibility breakpoint, the bacteria are considered susceptible.18
Avibactam does not inhibit class B enzymes (metallo-β-lactamases) and is not able to inhibit many of the class D enzymes.

Abbreviations:

BL, β-lactam; BLI, β-lactamase inhibitor; CRE, carbapenem-resistant Enterobacterales; CTX-M, cefotaximase-Munich; ESBL, extended-spectrum β-lactamase; EUCAST, European Committee on Antimicrobial Susceptibility Testing; HAP, hospital-acquired pneumonia; KPC, Klebsiella pneumoniae carbapenemase; MBL, metallo-β-lactamase; MDR, multidrug infections; OXA, oxacillinase; SHV, sulphydryl variable; TEM, Temoniera; VAP, ventilator-acquired pneumonia; XDR, extensively drug-resistant.

References:

Liscio JL, et al. Int J Antimicrob Agents 2015;46:266–71.Mazuski JE, et al. Surg Infect 2017;18:1–76.Pogue JM, et al. Clin Infect Dis 2019;68:519–24.ZAVICEFTA Summary of Product Characteristics, 2022.Zhanel GG, et al. Drugs 2013;73:159–77.Lagacé-Wiens P, et al. Core Evidence 2014;9:13–25.Bush K. Int J Antimicrob Agents 2015;46:483–93.Wright H, et al. Clin Microbiol Infect 2017;23:704–12.Munita J, et al. Clin Infect Dis 2017;65:158–61.Zerbaxa. Summary of Product Characteristics, 2015.Sader H, et al. Diagn Microbiol Infect Dis 2015;83:389–94.Walkty A, et al. Antimicrob Agents Chemother 2011;55:2992–4.Lomovskaya O, et al. Antimicrob Agents Chemother 2017;61:e01443-17.Recarbrio. Summary of Product Characteristics, 2020.Recarbrio. Prescribing Information, 2019.Smith JR, et al. Pharmacotherapy 2020;40:343–56.Sader HS, et al. Diagn Microbiol Infect Dis 2020;96:114833 and supplementary information.The Open University. Antimicrobial susceptibility testing. Available at: https://www.open.edu/openlearncreate/mod/oucontent/view.php?id=172394&printable=1. (last accessed July 2022).
Preparatomtale
PP-ZVA-NOR-0141 Mai 2023
Om ZAVICEFTA

Pfizer AS, Org.nr 915 213 596

Postadresse: Postboks 3, 1324 Lysaker
Besøksadresse: Drammensveien 288, 0283 Oslo

Tlf.: +47 67 52 61 00


PP-BCP-NOR-0001 juni 2023

Copyright © 2023 Pfizer AS. Innholdet er rettighetsbeskyttet.

 




 

Du forlater nå PfizerPro.no
Nettstedet du kommer til er hverken eid eller kontrollert av Pfizer i Norge. Pfizer i Norge er ikke ansvarlig for innholdet på nettstedet du kommer til.
Kun for helsepersonell

Dette nettstedet er kun for helsepersonell.

Jeg bekrefter at jeg er helsepersonell som definert i legemiddelforskriften §13-1.

Ved å velge "nei" vil du komme til Pfizer.no som er åpen for allmenheten.

Ja Nei